Radcliffe Medical Education is proud to announce a new one-day event New Horizons in Amyloidosis (NHA), specially focused on providing an update on the diagnosis and treatment of cardiac amyloidosis and its sequelae in recognition of this rapidly developing field.  

Hosted on www.radcliffecardiology.com, the event will be streamed on Wednesday 28 February 2024. This programme is designed to educate healthcare professionals on the evolving management practices in cardiac amyloidosis and is tailored to update and educate a variety of professionals including cardiologists, imaging specialists, electrophysiologists, primary care physicians, hematologists, and cardiac nurse practitioners.

This event, led by Course Director Prof Rodney Falk (Brigham and Women’s Hospital in Boston, US), will feature a distinguished group of faculty members who are renowned experts in the field of cardiac amyloidosis. The faculty will encompass a diverse range of medical specialties, facilitating a comprehensive, multidisciplinary approach.

Register now - We look forward to welcoming you to this first-time event.

*New Horizons in Amyloidosis’s programme will be submitted for accreditation to the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 4 CME points, equating to 4 hours of learning. Physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™.

Learning Objectives

• Increase the awareness of at-risk patients; 
• Improve understanding of screening procedures; 
• Provide guidance on the use of imaging for cardiac amyloidosis diagnosis; 
• Improve awareness on current and emerging treatment; 
• Provide guidance on the management of key comorbidities. 
   

Target Audience

• Cardiologists (device implanters, heart failure)
• Imaging Specialists
• Electrophysiologists
• Primary care
• Haematologists
• Cardiac Nurse Practitioners